Tekmira Pharmaceuticals

Tekmira Pharmaceuticals: Though human testing of Tekmira Pharmaceuticals ' treatment TKM-Ebola was put on hold last month due to safety concerns, investors scrambled to buy its stock Friday, sending shares up 7.5 per cent to $13.77 in Nasdaq trading Friday, and up more than 50 per cent over the past two weeks. , according to Canadian Broadcasting Corporation, CBC. Tekmira had previously published proof-of-concept data that showed its treatment resulted in 100 per cent protection from a lethal dose of Zaire Ebola virus in infected primates. The price of shares in a B.C. pharmaceutical company that has been working to develop an Ebola counter-measure rose sharply this week with news that the deadly outbreak in West Africa has intensified. Ebola belongs to a family of viruses that can cause serious hemorrhagic fevers. The recent outbreak, which has killed 729 people in four different countries since February , is the worst since the disease was discovered in the mid-1970s . (news.financializer.com). As reported in the news.